China's Jiangsu Hengrui to grant license for cancer drug to Swiss unit of India's Glenmark
24/09/2025 11:09
Sept 24 (Reuters) - China's Jiangsu Hengrui Pharmaceuticals 600276.SS said on Wednesday it has agreed to grant a paid license for its innovative cancer drug trastuzumab rezetecan to the Swiss unit of India's Glenmark Pharmaceuticals GLEN.NS. Under the agreement, Hengrui will receive an upfront payment of $18 million and can get milestone payments of up to $1.09 billion from Switzerland's Glenmark Specialty S.A. (Reporting by Shivangi Lahiri in Bengaluru; Editing by Leroy Leo) ((Shivangi.Lahiri@thomsonreuters.com))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter